ORIC Pharmaceuticals Enhances Visibility at December Conferences

ORIC Pharmaceuticals' Upcoming Presentations

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a company that specializes in clinical-stage oncology therapies, is dedicated to the fight against cancer. The management team is poised to participate in significant investor conferences this December.

Key Events in December

The company has announced its participation in two prominent investor events. First is the 7th Annual Evercore HEALTHCONx Conference, where team members will engage in a fireside chat scheduled for December 4, at 2:35 p.m. ET. This offers a fantastic opportunity for investors to understand ORIC's unique approach to cancer treatment.

Following this, ORIC will participate in the Citi's 2024 Global Healthcare Conference on December 5, at 11:00 a.m. ET. During this panel titled "Novel Mechanisms in Oncology II", the focus will be on innovative strategies and approaches in oncology.

Webcast Availability

For those unable to attend, the company will host live webcasts of these discussions on the investor section of its official website. These webcasts will also be available for replay for a period of 90 days post-event, ensuring that all interested parties have access to the valuable insights shared.

Innovative Cancer Therapies

ORIC Pharmaceuticals is not just participating in these conferences. It is at the forefront of oncology advancements with its leading programs aimed at overcoming mechanisms of therapeutic resistance. The company focuses on enhancing the efficacy of cancer treatments, which is a pressing need in modern medicine.

Leading Product Candidates

Among its noteworthy clinical stage candidates, ORIC is developing ORIC-114, a targeted inhibitor that addresses EGFR and HER2 mutations across various cancers. This indicates a strong commitment to precision medicine and tailored treatment options that cater to individual patient profiles.

Another key candidate is ORIC-944, an allosteric inhibitor targeting the polycomb repressive complex 2 (PRC2), specifically designed for the treatment of prostate cancer. Additionally, ORIC-533, an orally bioavailable small molecule, is being crafted to disrupt the CD73 pathway, crucial in chemotherapy resistance.

Corporate Vision and Goals

The overarching vision of ORIC Pharmaceuticals is centered on improving patient outcomes through innovative research and development. The company believes in tackling the fundamental challenges in cancer treatment head-on by developing therapies that can navigate the hurdles presented by resistance mechanisms.

Company Presence

With operational bases in South San Francisco and San Diego, California, ORIC leverages the rich biotech ecosystem of the region. The commitment to research and patient-centric solutions is evident in their extensive pipeline and active engagement with the investment community.

Contact Information

For further inquiries, individuals can reach out to Dominic Piscitelli, Chief Financial Officer of ORIC Pharmaceuticals. He is available via email for any questions regarding the company's operations or upcoming events.

Email: dominic.piscitelli@oricpharma.com or info@oricpharma.com

Frequently Asked Questions

What is ORIC Pharmaceuticals known for?

ORIC Pharmaceuticals is focused on developing innovative treatments for cancer, particularly targeting mechanisms of resistance.

When will the investor conferences take place?

The conferences are scheduled for December 4 and December 5, 2024.

How can one access the webcasts?

Live webcasts can be accessed through the investor section of the ORIC Pharmaceuticals website and will be available for replay for 90 days.

What are some key therapies in ORIC's pipeline?

ORIC's pipeline includes ORIC-114, ORIC-944, and ORIC-533, each targeting different cancer treatment challenges.

Who can be contacted for more information about ORIC Pharmaceuticals?

Dominic Piscitelli, the Chief Financial Officer, is the primary contact for inquiries related to the company's activities and events.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.